Omnibus spending package
This article was originally published in The Gray Sheet
Executive Summary
President Clinton signs fiscal 2000 Omnibus Consolidated Appropriations Act at a White House ceremony Nov. 29. HR 3194 includes $16 bil. over five years to restore some planned BBA 1997 cuts to Medicare providers and Medicare+Choice plans. The legislation was adopted by the House Nov. 18 and the Senate on Nov. 19. In his remarks, Clinton highlighted increased investment in biomedical research, mental health and pediatric training, including a $2.3 bil. increase to $17.9 bil. for the National Institutes of Health. Clinton noted that passage of a Patients' Bill of Rights and Medicare reform, including a voluntary prescription drug benefit, are among the Administration's priorities for next year
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.